Filing Details

Accession Number:
0000899243-19-023936
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-19 19:05:35
Reporting Period:
2019-09-17
Accepted Time:
2019-09-19 19:05:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1773427 Springworks Therapeutics Inc. SWTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1578965 Adam Koppel 200 Clarendon Street
Boston MA 02116
No No Yes No
1702957 Lawrence Jeffrey Schwartz C/O Bain Capital Life Sciences Investors
Llc, 200 Clarendon Street
Boston MA 02116
Yes No Yes No
1703031 Bain Capital Life Sciences Investors, Llc 200 Clarendon Street
Boston MA 02116
No No Yes No
1786351 Bc Sw, Lp 200 Clarendon Street
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-17 6,078,103 $0.00 6,078,103 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2019-09-17 1,053,204 $0.00 7,131,307 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2019-09-17 150,000 $18.00 7,281,307 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2019-09-17 6,078,103 $0.00 6,078,103 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2019-09-17 1,053,204 $0.00 1,053,204 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date.
  2. Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date.
  3. Represents shares purchased in the Issuer's initial public offering.
  4. Represents shares held directly by BC SW, L.P.
  5. Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
  6. Jeffrey Schwartz is a director of the Issuer.